Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5004646 | 0.98 | KMT2A (0.76) | KMT2AOPRM1OPRD1HSD17B3NPC1 | |
| Bromide SCHEMBL3845600 | 0.98 | KMT2A (0.76) | KMT2AOPRM1OPRD1HSD17B3NPC1 | |
| Bromide SCHEMBL5004644 | 0.97 | KMT2A (0.74) | KMT2AOPRM1OPRD1HSD17B3NPC1 | |
| SCHEMBL6938197 | 0.86 | KMT2A (0.97) | KMT2AOPRM1OPRD1NPC1RAB9A | |
| Alagebrium SCHEMBL1820212 | 0.86 | KMT2A (0.71) | KMT2AOPRM1OPRD1NPC1RAB9A | |
| Bromide SCHEMBL3849500 | 0.85 | KMT2A (0.74) | KMT2AOPRM1OPRD1NPC1RAB9A | |
| Bromide SCHEMBL2956158 | 0.85 | KMT2A (1.00) | KMT2AOPRM1OPRD1NPC1RAB9A | |
| Alagebrium SCHEMBL225618 | 0.84 | KMT2A (0.69) | KMT2AOPRM1OPRD1ALDH1A1POLB | |
| Alagebrium SCHEMBL1648822 | 0.84 | KMT2A (0.74) | KMT2AOPRM1OPRD1L3MBTL1AHR | |
| Bromide SCHEMBL3849441 | 0.83 | KMT2A (0.63) | KMT2AOPRM1OPRD1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257272-A4 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1257272-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | Alteon, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6458819-B1 | INHIBITION OF FORMATION OF ADVANCED GLYCOSYLATION OF PROTEINS AND TO BREAKING THE CROSS-LINKS THAT FORM BETWEEN ADVANCED GLYCOSYLATION ENDPRODUCTS OR BETWEEN AGES AND OTHER PROTEINS. | ALTEON, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | SYNVISTA THERAPEUTICS, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001062250-A1 | THIAZOLIUM COMPOUNDS AND TREATMENTS OF DISORDERS ASSOCIATED WITH PROTEIN AGING | ALTEON, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055527-A1 | Thiazolium compounds and treatments of disorders associated with protein aging | TTR, RBP4, COL2A1 | KMT2A 4558/4885OPRM1 4413/4885OPRD1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.